First author, reference | Number of patients | Reperfused patients (%) | FABP sensitivity (%) | FABP specificity (%) | Myoglobin sensitivity (%) | Myoglobin specificity (%) | CK-MB sensitivity (%) | CK-MB specificity (%) |
Abe7 | 31 | 65 | – | – | 95 | 100 | – | – |
Ishii25 | 49 | 65 | – | – | 97 | 100 | 84 | 100 |
Ishii21 | 45 | 67 | 97 | 100 | 93 | 100 | – | – |
Miyata24 | 63 | 71 | – | – | 100 | 89 | 91 | 67 |
Ohman26 | 207 | 71 | – | – | – | – | 78 | 67 |
Tanasijevic23 | 27 | 70 | – | – | 89 | 100 | 83 | 100 |
Zabel6 4-150 | 63 | 73 | – | – | 94 | 88 | 85 | 71 |
Present study: | ||||||||
• Increase rate FABP | 115 | 75 | 71 | 69 | 67 | 71 | 52 | 75 |
• Increase rate FABP and QHBDH72 | 115 | 75 | 74 | 93 | 73 | 89 | 77 | 71 |
↵4-150 Blood sampling 90 minutes after treatment.